| Autor: |
Bartlett, Alastair I. Starcyznski, Jane Robson, Tammy and MacLellan, Alex Campbell, Fiona M. van de Vekle, Cornelis J. H. and Hasenburg, Annette Markopoulos, Christos Seynaeve, Caroline and Rea, Daniel Bartlett, John M. S. |
| Jazyk: |
angličtina |
| Rok vydání: |
2011 |
| Popis: |
Heterogeneous expression or amplification is a challenge to HER2 diagnostics. A guideline defines heterogeneity as the presence of between 5% and 50% cells with HER2/CEP17 ratios of more than 2.20. We audited the frequency of such cells and their clinical impact in the results from 2 pathology laboratories combined with data from the TEAM [Tamoxifen vs Exemestane Adjuvant Multicentre] pathology study. HER2 reports were scanned and the percentages of amplified cells reported. Of 6,461 eligible cases, 754 (11.7%) exhibited 50% or more cells with ratios of more than 2.20, which is “amplified” by College of American Pathologists guidelines. Of the cases, 2,166 (33.5%) exhibited more than 5% but less than 50% of cells with HER2/CEP17 ratios of more than 2.20, or “heterogeneous amplification.” No prognostic impact was observed when fewer than 30% of cells exhibited ratios of more than 2.20. All amplified cases with 30% to 50% of cells with ratios more than 2.20 were identified as such by United Kingdom guidelines. The percentage of tumor cells with HER2/CEP17 ratios more than 2.20 does not identify cases with heterogeneous amplification or poor outcome. A modified approach for identification of true heterogeneous amplification is suggested. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
